Migraine with aura

Summary

Migraine with aura (MONDO:0005475) is a disease with 3 cohort genes (13 GWAS associations across 12 studies) and 84 clinical trials. Top therapeutic interventions include dihydroergotamine, sumatriptan, and amitriptyline.

At a glance

• Cohort genes: 3
• GWAS associations: 13
• ClinVar variants: 7
• Clinical trials: 84

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	migraine with aura
Mondo ID	MONDO:0005475
MeSH	D020325
DOID	DOID:10024
ICD-10-CM	G43.1
ICD-11	525744634
NCIT	C117005
SNOMED CT	4473006
UMLS	C0154723
MedGen	57822
Is cancer (heuristic)	no

Data availability: 7 ClinVar variants · 13 GWAS associations (12 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › migraine disorder › migraine with aura

Related subtypes (1): migraine without aura

Subtypes (2): familial or sporadic hemiplegic migraine, migraine with brainstem aura

Genetics & variants

GWAS landscape

13 GWAS associations across 12 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs2983896	3e-26	FHL5	?
rs2052692	1e-24	IRAG1	?
rs3798293	1e-12	FHL5	?
rs11172113	2e-10	LRP1	?
rs77630941	7e-10	CUX1	?	28.37
rs146778855	1e-08	CDH18	?	20.63
rs112433120	1e-08	IGKV3OR2-268 - LINC01943	?
rs117608715	2e-08	NOL3	?	22.74
rs150592309	9e-08	ZNF511-PRAP1	?	21.72
rs1364402	4e-06	CHRM2	?	1.19
rs2076054	8e-06	BPIFC	C	1.12

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST011059	Guo Y	2020	59,674	316,078	A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine.
GCST011060	Guo Y	2020	59,674	316,078	A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine.
GCST011061	Guo Y	2020	59,674	316,078	A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine.
GCST003722	Gormley P	2016	6,332	144,883	Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine.
GCST002080	Anttila V	2013	5,118	74,239	Genome-wide meta-analysis identifies new susceptibility loci for migraine.
GCST90477543	Verma A	2024	4,445	441,492	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477542	Verma A	2024	1,484	118,840	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481049	Verma A	2024	1,484	118,840	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477541	Verma A	2024	895	58,139	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651463	Liu TY	2025	283	220,421	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	11

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	4

Functional consequences

Consequence	Count
intron_variant	9
intergenic_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs2983896	6	96581995	G>A	0.05	intron_variant	FHL5	3e-26	Tier 4: intronic/intergenic
rs2052692	11	10646094	A>C,G	0.05	intron_variant	IRAG1	1e-24	Tier 4: intronic/intergenic
rs3798293	6	96585494	A>G	0.05	intron_variant	FHL5	1e-12	Tier 4: intronic/intergenic
rs11172113	12	57133500	T>C,G	0.05	intron_variant	LRP1	2e-10	Tier 4: intronic/intergenic
rs77630941	7	102217020	T>C		intron_variant	CUX1	7e-10	Tier 4: intronic/intergenic
rs146778855	5	20412078	C>T		intergenic_variant	CDH18	1e-08	Tier 4: intronic/intergenic
rs112433120	2	87402135	T>A,C	0.05	intergenic_variant	IGKV3OR2-268 - LINC01943	1e-08	Tier 4: intronic/intergenic
rs117608715	16	67172270	C>G,T		intron_variant	NOL3	2e-08	Tier 4: intronic/intergenic
rs150592309	10	133346685	G>A		intron_variant	ZNF511-PRAP1	9e-08	Tier 4: intronic/intergenic
rs1364402	7	136899616	T>C	0.09	intron_variant	CHRM2	4e-06	Tier 4: intronic/intergenic
rs2076054	22	32436887	C>T	0.26	intron_variant	BPIFC	8e-06	Tier 4: intronic/intergenic

ClinVar germline variants

7 retrieved; paginated sample, class counts are floors:

3 pathogenic, 2 uncertain significance, 2 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
523300	GRCh37/hg19 Xq28(chrX:153575976-153586768)	FLNA	Pathogenic	criteria provided, single submitter
523301	GRCh37/hg19 Xq28(chrX:153588672-153609996)	FLNA	Pathogenic	criteria provided, single submitter
812745	NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg)	NOTCH3	Pathogenic	no assertion criteria provided
812743	NM_000435.3(NOTCH3):c.1162T>C (p.Cys388Arg)	NOTCH3	Likely pathogenic	no assertion criteria provided
812744	NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser)	NOTCH3	Likely pathogenic	criteria provided, single submitter
523553	NM_080916.3(DGUOK):c.278G>A (p.Gly93Glu)	DGUOK	Uncertain significance	criteria provided, single submitter
523554	NM_080916.3(DGUOK):c.65C>T (p.Pro22Leu)	DGUOK	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 16 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
DGUOK	Orphanet:279934	Mitochondrial DNA depletion syndrome, hepatocerebral form due to DGUOK deficiency
DGUOK	Orphanet:329314	Adult-onset multiple mitochondrial DNA deletion syndrome due to DGUOK deficiency
FLNA	Orphanet:1826	Frontometaphyseal dysplasia
FLNA	Orphanet:2301	Congenital short bowel syndrome
FLNA	Orphanet:2484	Melnick-Needles syndrome
FLNA	Orphanet:482606	X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome
FLNA	Orphanet:555877	FLNA-related X-linked myxomatous valvular dysplasia
FLNA	Orphanet:75497	X-linked Ehlers-Danlos syndrome
FLNA	Orphanet:88630	Terminal osseous dysplasia-pigmentary defects syndrome
FLNA	Orphanet:90650	Otopalatodigital syndrome type 1
FLNA	Orphanet:90652	Otopalatodigital syndrome type 2
FLNA	Orphanet:98892	Periventricular nodular heterotopia
FLNA	Orphanet:99811	Neuronal intestinal pseudoobstruction
NOTCH3	Orphanet:136	Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
NOTCH3	Orphanet:2591	Infantile myofibromatosis
NOTCH3	Orphanet:2789	Lateral meningocele syndrome

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
DGUOK	HGNC:2858	ENSG00000114956	Q16854	Deoxyguanosine kinase, mitochondrial	clinvar
FLNA	HGNC:3754	ENSG00000196924	P21333	Filamin-A	clinvar
NOTCH3	HGNC:7883	ENSG00000074181	Q9UM47	Neurogenic locus notch homolog protein 3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
DGUOK	Deoxyguanosine kinase, mitochondrial	Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine.
FLNA	Filamin-A	Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins.
NOTCH3	Neurogenic locus notch homolog protein 3	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	9.7×	0.157
Kinase	1	9.2×	0.157
Scaffold/PPI	1	5.8×	0.164

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
DGUOK	Kinase	yes	2.7.1.113	DCK/DGK, P-loop_NTPase, DNK_dom
FLNA	Antibody/Immunoglobulin	yes		Filamin/ABP280_rpt, Actinin_actin-bd_CS, CH_dom
NOTCH3	Scaffold/PPI	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, Notch_dom

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
popliteal artery	2
right coronary artery	2
tibial artery	2
adenohypophysis	1
olfactory segment of nasal mucosa	1
pituitary gland	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
DGUOK	297	ubiquitous	marker	adenohypophysis, olfactory segment of nasal mucosa, pituitary gland
FLNA	285	ubiquitous	marker	right coronary artery, popliteal artery, tibial artery
NOTCH3	273	ubiquitous	marker	popliteal artery, tibial artery, right coronary artery

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FLNA	5,321
NOTCH3	4,403
DGUOK	201

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FLNA	P21333	26
NOTCH3	Q9UM47	6
DGUOK	Q16854	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 14. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective LFNG causes SCDO3	1	761.3×	0.008	NOTCH3
Pre-NOTCH Processing in the Endoplasmic Reticulum	1	634.4×	0.008	NOTCH3
Noncanonical activation of NOTCH3	1	475.8×	0.008	NOTCH3
OAS antiviral response	1	423.0×	0.008	FLNA
GP1b-IX-V activation signalling	1	317.2×	0.008	FLNA
Purine salvage	1	292.8×	0.008	DGUOK
Cell-extracellular matrix interactions	1	223.9×	0.008	FLNA
Pre-NOTCH Processing in Golgi	1	211.5×	0.008	NOTCH3
RHO GTPases activate PAKs	1	181.3×	0.009	FLNA
NOTCH3 Activation and Transmission of Signal to the Nucleus	1	158.6×	0.009	NOTCH3
NOTCH3 Intracellular Domain Regulates Transcription	1	146.4×	0.009	NOTCH3
Notch-HLH transcription pathway	1	135.9×	0.009	NOTCH3
Pre-NOTCH Transcription and Translation	1	40.9×	0.026	NOTCH3
Platelet degranulation	1	29.3×	0.034	FLNA

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
guanosine metabolic process	1	5617.3×	0.002	DGUOK
dGTP metabolic process	1	5617.3×	0.002	DGUOK
purine deoxyribonucleoside metabolic process	1	5617.3×	0.002	DGUOK
regulation of membrane repolarization during atrial cardiac muscle cell action potential	1	5617.3×	0.002	FLNA
regulation of membrane repolarization during cardiac muscle cell action potential	1	5617.3×	0.002	FLNA
glomerular capillary formation	1	1872.4×	0.004	NOTCH3
tubulin deacetylation	1	1872.4×	0.004	FLNA
dAMP salvage	1	1872.4×	0.004	DGUOK
formation of radial glial scaffolds	1	1404.3×	0.004	FLNA
adenylate cyclase-inhibiting dopamine receptor signaling pathway	1	1123.5×	0.005	FLNA
establishment of Sertoli cell barrier	1	1123.5×	0.005	FLNA
protein localization to bicellular tight junction	1	936.2×	0.005	FLNA
negative regulation of transcription by RNA polymerase I	1	802.5×	0.005	FLNA
blood coagulation, intrinsic pathway	1	702.2×	0.005	FLNA
neuroblast differentiation	1	702.2×	0.005	NOTCH3
mitochondrial ATP synthesis coupled electron transport	1	624.1×	0.006	DGUOK
positive regulation of platelet activation	1	432.1×	0.007	FLNA
positive regulation of integrin-mediated signaling pathway	1	432.1×	0.007	FLNA
positive regulation of actin filament bundle assembly	1	401.2×	0.007	FLNA
actin crosslink formation	1	401.2×	0.007	FLNA
wound healing, spreading of cells	1	374.5×	0.007	FLNA
positive regulation of potassium ion transmembrane transport	1	330.4×	0.007	FLNA
positive regulation of neuron migration	1	330.4×	0.007	FLNA
neuron fate commitment	1	267.5×	0.009	NOTCH3
positive regulation of neural precursor cell proliferation	1	255.3×	0.009	FLNA
obsolete negative regulation of DNA-binding transcription factor activity	1	244.2×	0.009	FLNA
megakaryocyte development	1	234.1×	0.009	FLNA
artery morphogenesis	1	224.7×	0.009	NOTCH3
receptor clustering	1	208.1×	0.009	FLNA
protein localization to cell surface	1	165.2×	0.011	FLNA

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

12 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Anisodine Hydrobromide	Phase 3
Caffeine	Phase 3
Dihydroergotamine	Phase 3
Eletriptan	Phase 3
Promethazine	Phase 3
Rizatriptan	Phase 3
Sumatriptan	Phase 3
Amiloride	Phase 2
Candesartan	Phase 2
Dronabinol	Phase 2
Propranolol	Phase 2
Ramelteon	Phase 2

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FLNA	1	2
NOTCH3	1	2
DGUOK	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
MOLIBRESIB	2	FLNA
VAREGACESTAT	2	NOTCH3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FLNA	7	Binding:7
NOTCH3	3	Binding:3
DGUOK	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
DGUOK	2.7.1.113	deoxyguanosine kinase

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

2 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
MOLIBRESIB	2	FLNA
VAREGACESTAT	2	NOTCH3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	2	FLNA, NOTCH3
C	Druggable family + PDB, no drug	1	DGUOK
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DGUOK	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 84.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	52
PHASE3	11
PHASE2	11
PHASE4	5
EARLY_PHASE1	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01319825	PHASE4	UNKNOWN	Preventive Treatment of Episodic and Chronic Migraine
NCT01596166	PHASE4	COMPLETED	Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department
NCT05211154	PHASE4	TERMINATED	Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
NCT05214001	PHASE4	TERMINATED	Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
NCT06244823	PHASE4	UNKNOWN	The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab
NCT05484349	PHASE3	RECRUITING	TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）
NCT00334178	PHASE3	COMPLETED	Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
NCT00449540	PHASE3	COMPLETED	Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
NCT00471952	PHASE3	COMPLETED	Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
NCT00884663	PHASE2/PHASE3	COMPLETED	Candesartan Versus Propranolol for Migraine Prevention
NCT01814189	PHASE3	COMPLETED	Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment
NCT01859481	PHASE3	COMPLETED	Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
NCT03901482	PHASE3	COMPLETED	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
NCT04406649	PHASE3	COMPLETED	A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
NCT04726592	PHASE3	TERMINATED	Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
NCT04940390	PHASE3	COMPLETED	A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
NCT05416476	PHASE3	UNKNOWN	Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
NCT04063540	PHASE2	RECRUITING	Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
NCT00123201	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
NCT00285402	PHASE2	UNKNOWN	Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
NCT00311662	PHASE2	COMPLETED	Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
NCT00332007	PHASE2	COMPLETED	Tonabersat in the Prophylaxis of Migraine With Aura
NCT00505570	PHASE2	TERMINATED	PRIMA PFO Migraine Trial
NCT00534560	PHASE2	COMPLETED	Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
NCT00739024	PHASE2	TERMINATED	A Study of a Melatonin Receptor Agonist to Prevent Migraine
NCT00877838	PHASE2	UNKNOWN	Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura
NCT00920686	PHASE2	COMPLETED	Study of NXN 188 for the Treatment of Migraine With Aura
NCT03472378	PHASE2	COMPLETED	Can DFN-15 Terminate Migraine With Allodynia?
NCT03874832	PHASE1	COMPLETED	A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
NCT05337254	PHASE1	COMPLETED	A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
NCT02253004	EARLY_PHASE1	COMPLETED	Induction of Migraine Aura With Cilostazol
NCT02795351	EARLY_PHASE1	COMPLETED	Induction of Migraine Aura With Sildenafil
NCT03301441	Not specified	ACTIVE_NOT_RECRUITING	Sensitivity to Acute Cerebral Ischemia in Migrainers
NCT04715685	Not specified	RECRUITING	Mind Body Balance for Pediatric Migraine
NCT05889624	Not specified	RECRUITING	Responding With Evidence and Access for Childhood Headaches
NCT05903027	Not specified	RECRUITING	Gepant treAtments: EffectIveNess and tolERability (GAINER)
NCT06409832	Not specified	RECRUITING	RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409845	Not specified	RECRUITING	Effectiveness and Tolerability of Eptinezumab
NCT06414044	Not specified	ACTIVE_NOT_RECRUITING	Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
NCT06459635	Not specified	RECRUITING	Migraine Attack Pain Phase Prediction Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DIHYDROERGOTAMINE	4	15
SUMATRIPTAN	4	4
AMITRIPTYLINE	4	3
PROPRANOLOL	4	3
ERENUMAB	4	2
METOCLOPRAMIDE	4	2
RIMEGEPANT	4	2
TIZANIDINE	4	2
AMILORIDE	4	1
ATOGEPANT	4	1
CILOSTAZOL	4	1
CLORAZEPATE DIPOTASSIUM	4	1
DICLOFENAC	4	1
ELETRIPTAN HYDROBROMIDE	4	1
FREMANEZUMAB	4	1
GALCANEZUMAB	4	1
KETOPROFEN	4	1
KETOROLAC TROMETHAMINE	4	1
LASMIDITAN	4	1
MILNACIPRAN	4	1
RAMELTEON	4	1
ANISODINE HYDROBROMIDE	3	1
CANDESARTAN	3	1
TONABERSAT	2	3
DEXPROPRANOLOL	2	1
ENDOTHELIN	2	1
LEVCROMAKALIM	2	1
CHEMBL4585978	0	5
CHEMBL5072828	0	1
CHEMBL3775234	0	1